Stressgen Biotechnologies

Stressgen Biotechnologies was a biopharmaceutical company focused on developing innovative immunotherapies based on heat shock protein (HSP) technology. The company's primary research centered on the ability of HSPs to act as powerful molecular chaperones and adjuvants, stimulating the immune system to target specific viral and cancerous antigens. Its lead candidate, HspE7, was a recombinant fusion protein designed to treat diseases caused by the human papillomavirus (HPV), including genital warts and various dysplasias. Stressgen was a pioneer in the field of molecular chaperones and cellular stress response before being acquired by Nastech Pharmaceutical Company in 2006. The company also maintained a significant bioreagents division that provided specialized research tools to the global scientific community.